• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

    10/17/24 12:14:52 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPRX alert in real time by email
    SC 13G/A 1 Catalyst_Pharma_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    CATALYST PHARMACEUTICALS INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    14888U101

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    14888U101 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,252,354

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,685,330

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,685,330.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.8%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    14888U101 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      CATALYST PHARMACEUTICALS INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      355 ALHAMBRA CIRCLE SUITE 1250 CORAL GABLES FL 33134 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      14888U101

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    14888U101 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 5,685,330.00  
      (b) Percent of class: 4.8%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 5,252,354
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 5,685,330
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ý
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    14888U101 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $CPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CPRX

    DatePrice TargetRatingAnalyst
    2/4/2025$28.00Outperform
    Robert W. Baird
    11/18/2024$35.00Overweight
    Stephens
    3/14/2024$27.00Buy
    Citigroup
    3/7/2024$23.00Buy
    BofA Securities
    12/21/2023$30.00Outperform
    Oppenheimer
    8/24/2022$10.00 → $15.50Buy → Neutral
    ROTH Capital
    2/8/2022$9.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CPRX
    SEC Filings

    View All

    SEC Form PREM14A filed by Catalyst Pharmaceuticals Inc.

    PREM14A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

    5/28/26 4:56:14 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Catalyst Pharmaceuticals Inc.

    DEFA14A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

    5/12/26 9:05:28 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

    8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

    5/11/26 4:33:41 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief HR Officer Russo Gregg covered exercise/tax liability with 211 shares and converted options into 687 shares (SEC Form 4)

    4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

    2/19/26 5:04:15 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Vice President & CFO Kalb Michael Wayne converted options into 7,139 shares and covered exercise/tax liability with 2,080 shares, increasing direct ownership by 59% to 13,665 units (SEC Form 4)

    4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

    1/6/26 5:00:47 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Daly Richard J covered exercise/tax liability with 10,577 shares and converted options into 42,105 shares, increasing direct ownership by 13% to 271,266 units (SEC Form 4)

    4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

    1/6/26 5:00:30 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Catalyst Pharma with a new price target

    Robert W. Baird initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $28.00

    2/4/25 7:01:07 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on Catalyst Pharma with a new price target

    Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00

    11/18/24 8:40:25 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Catalyst Pharma with a new price target

    Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00

    3/14/24 7:36:28 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

    Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026 CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported financial results for the first quarter of 2026 and provided a business update. Financial Highlights For the Three Months Ended March 31, 20262025% Change(In thousands, except per share data)   Product Revenue, net$149,343$141,400              5.6%FIRDAPSE Product Revenue, net$98,859$83,731            18.1%AGAMREE Product Revenu

    5/11/26 4:12:45 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

    CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today. Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned. About Catalyst Pharmaceuticals, Inc.Catalyst Pharmac

    5/7/26 4:02:00 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

    As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. ("SERB") have entered into a Settlement Agreement ("Agreement") with Hetero Labs Ltd., Hetero USA, Grace Consulting Services, Inc., and Annora Pharma Private

    5/7/26 2:44:12 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

    SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

    11/14/24 9:55:56 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

    SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

    10/18/24 3:31:27 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

    SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

    10/17/24 12:14:52 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Financials

    Live finance-specific insights

    View All

    Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

    Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026 CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported financial results for the first quarter of 2026 and provided a business update. Financial Highlights For the Three Months Ended March 31, 20262025% Change(In thousands, except per share data)   Product Revenue, net$149,343$141,400              5.6%FIRDAPSE Product Revenue, net$98,859$83,731            18.1%AGAMREE Product Revenu

    5/11/26 4:12:45 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

    CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today. Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned. About Catalyst Pharmaceuticals, Inc.Catalyst Pharmac

    5/7/26 4:02:00 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026

    CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026. Catalyst's management team will host a conference call and webcast on Tuesday, May 12, 2026, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate:May 12, 2026Time:8:30 AM ETUS/Canada Dial-in

    4/28/26 8:03:00 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

    CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da

    8/4/25 8:03:00 AM ET
    $CPRX
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

    CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company's President and Chief Executive Officer, Richard J. Daly, and will serve as a member of the Company's executive leadership team. He succeeds Dr. Gary Ingenito, who is retiring after a successful career and will support the transition in a consulting capacity. "We are pleased to welcome Dr. Andrews to Catalyst. In addition to his foundational work in clinical practice in some of the country's most prestigious hospitals, he b

    6/2/25 8:03:00 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

    CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene. "At Catalyst, our commitment to the community is unwavering, particularly in times of crisis," said Richard J. Daly, President and CEO of Catalyst. "We extend our heartfelt sympathies to those affected by Hurricane Helene and are honored to contribute to the

    10/8/24 8:03:00 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care